Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells

Journal of Urology

Volumn 161, Issue 3, 1999, Pages 777-782

  Höltl, Lorenz ^a   Rieser, Claudia ^a   Papesh, Christine ^a   Ramoner, Reinhold ^a   Herold, Manfred ^a   Klocker, Helmut ^a   Radmayr, Christian ^a   Stenzl, Arnulf ^a   Bartsch, Georg ^a   Thurnher, Martin ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Carcinoma, renal cell; Dendritic cells; Immunotherapy

Indexed keywords

CANCER VACCINE; CD83 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CELL LYSATE; CELL SUBPOPULATION; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; FEVER; HUMAN; IMMUNOGLOBULIN PRODUCTION; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINE PRODUCTION;

EID: 0344678389     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61767-1     Document Type: Article

References (20)

1. Motzer, R. J., Bander, N. H. and Nanus, D. M.: Renal-cell carcinoma New Engl. J. Med., 335: 865, 1996.
2. Mulders, P., Figlin, R., deKernion, J. B., Wiltrout, R., Linehan, M., Parkinson, D., deWolf, W. and Belldegrun, A.: Renal cell carcinoma: recent progress and future directions. Cancer Res., 57: 5189, 1997.
3. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Rubin, S. T., Seipp, C. A., Simpson, C. G. and White, D. E.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl. J. Med., 316: 889, 1987.
4. Vogelzang, N. J., Lipton, A. and Figlin, R. A.: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J. Clin. Oncol., 11: 1809, 1993.
5. Figlin, R. A., Pierce, W. C., Kaboo, R., Tso, C. L., Moldawer, N., Gitlitz, B., deKernion, J. and Belldegrun, A.: Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J. Urol., 158: 740, 1997.
6. Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., Hauda, K. M., Beck, L. A., Leiferman, K. M., Owens, A. H., Jr., Piantadosi, S., Dranoff, G., Mulligan, R. C., Pardoll, D. M. and Marshall, F. F.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res., 57: 1537, 1997.
7. Thurnher, M., Klocker, H., Papesh, C., Ramoner, R., Radmayr, C., Hobisch, A., Gastl, G., Romani, N., Ebner, S., Böck, G. and Bartsch, G.: Dendritic cells for the immunotherapy of renal cell carcinoma. Urol. Int., 59: 1, 1997.
8. Banchereau, J. and Steinman, R. M.: Dendritic cells and the control of immunity. Nature, 392: 245, 1998.
9. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. and Schadendorf, D.: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Natl. Med., 4: 328, 1998.
10. Salgaller, M. L., Lodge, P. A., McLean, J. G., Tjoa, B. A., Loftus, D. J., Ragde, H., Kenny, G. M., Rogers, M., Boynton, A. L. and Murphy, G. P.: Report of immune monitoring of prostate cancer patients undergoing T cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate, 35: 144, 1998.
11. Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G. and Levy, R.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Natl. Med., 2: 52, 1996.
12. Rieser, C., Papesh, C., Herold, M., Bock, G., Ramoner, R., Klocker, H., Bartsch, G. and Thurnher, M.: Differential deactivation of human dendritic cells by endotoxin desensitization: role of tumor necrosis factor-alpha and prostaglandin E2. Blood, 91: 3112, 1998.
13. Rieser, C., Bock, G., Klocker, H., Bartsch, G. and Thurnher, M.: Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J. Exp. Med., 186: 1603, 1997.
14. Thurnher, M., Papesh, C., Ramoner, R., Gastl, G., Bock, G., Radmayr, C., Klocker, H. and Bartsch, G.: In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Exp. Hematol., 25: 232, 1997.
15. Thurnher, M., Ramoner, R., Gastl, G., Radmayr, C., Bock, G., Herold, M., Klocker, H. and Bartsch, G.: Bacillus Calmette-Guerin mycobacteria stimulate human blood dendritic cells. Int. J. Cancer, 70: 128, 1997.
16. Ramoner, R., Rieser, C., Herold, M., Klocker, H., Bartsch, G., Stenzl, A. and Thurnher, M.: Activation of human dendritic cells by bacillus Calmette-Guerin. J. Urol., 159: 1488, 1998.
17. Cella, M., Engering, A., Pinet, V., Pieters, J. and Lanzavecchia, A.: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature, 388: 782, 1997.
18. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A. and Alber, G.: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med., 184: 747, 1996.
19. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H. and White, D. E.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Natl. Med., 4: 321, 1998.
20. + blood dendritic cells as a vaccine for the active, specific immunotherapy of metastatic renal cell carcinoma. Lancet, 352: 1358, 1998.